ClinicalTrials.gg
CompletedNCT03744637Updated Jun 4, 2025Results posted

A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002)

A Phase 1 interventional study of Frespaciguat and Placebo in Pulmonary Arterial Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in Moldova, Republic of. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc — 3 open to participants now, 5 under way, 1 of them phase 3. Pulmonary Arterial Hypertension · Merck & Co., Inc.

Enrollment
12th of 17
25 · median 46
Started
2019
with 1 other
Phase 1
4 of 17
none open now
Registered
6th of 17
by date

Among the 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc, this one is the 12th largest by enrollment, is one of 2 that started in 2019, is one of 4 in phase 1, and was the 6th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc, or all of them as a file.
02

Study summary

This study of frespaciguat in participants with Group 1 pulmonary arterial hypertension (PAH) will assess the safety, tolerability and pharmacokinetics (PK) of inhaled frespaciguat. There is no formal hypothesis to be tested.

Read the detailed description

In Part 1, one panel (Panel A) of up to 8 participants will dose in up to 3 dosing periods, with a minimum washout of 7 days between dosing periods. In each dosing period, 6 participants will receive frespaciguat and 2 will receive placebo, with 2 different participants receiving placebo in each of the dosing periods. Review of available safety data will occur prior to escalating to the next dose level.

Participants from Part 1 may continue into Part 2, which will assess safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single-dose inhaled frespaciguat. Three additional panels of participants (Panels B, C and D) will be enrolled into Part 2. Participants in Panel A will participate in 2 open-label dosing periods to assess PD measures associated with right heart catherization (RHC) [Period 2] and functional respiratory imaging (FRI) [Period 3]. Participants in Panels B, C, and D will participate in 3 dosing periods: Period 1 (open-label assessment of safety/tolerability and PK), Period 2 (FRI period) and Period 3 (RHC period).

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be or have suspected Group 1 pulmonary hypertension as defined by the Nice 2013 Clinical Classification, including: idiopathic PAH, heritable PAH, drug- or toxin-induced PAH, or PAH associated with connective tissue disease or congenital heart disease
  • Have a (BMI) ≤35 kg/m2,
  • Female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: She is a woman of nonchildbearing potential (WONCBP) or is a and using a method that is highly effective (with a failure rate of \<1% per year), with low user dependency or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis)
  • Male participants are eligible to participate if they agree to the following during the intervention period and for at least 14 days, corresponding to time needed to eliminate study intervention(s) after the last dose of study intervention: Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent or must agree to use contraception unless confirmed to be azoospermic (Vasectomized) or secondary to medical cause.
  • Have a clinical indication for right heart catheterization (RHC) as part of initial work-up or ongoing medical management
  • Panel A: Have history of RHC within 3 years of starting study medication demonstrating mean pulmonary artery pressure of ≥ 27 mmHg and pulmonary vascular resistance (PVR) of ≥ 300 dynes/sec/cm5
  • Panels B/C/D: Have history of RHC within 3 years of starting study medication demonstrating mean pulmonary artery pressure of ≥ 27 mmHg and PVR of ≥ 300 dynes/sec/cm5 OR have an echocardiogram performed by the investigator at screening or within 1 year of screening demonstrating pulmonary artery systolic pressure ≥ 50 mmHg in conjunction with 1 or more of the following: tricuspid regurgitation velocity > 3.0 m/s and or significant right heart enlargement and or reduced right heart function.

Exclusion criteria

Exclusion Criteria:

  • Has pulmonary hypertension subtypes including the following according to Nice 2013 Clinical Classification: human immunodeficiency () infection, portal hypertension, schistosomiasis, chronic hemolytic anemia, pulmonary veno-occlusive disease (PVOD) and or pulmonary capillary hemangiomatosis (PCH), persistent pulmonary hypertension of the newborn (PPHN), pulmonary hypertension owing to left heart diseases, left ventricular systolic dysfunction, left ventricular diastolic dysfunction, valvular disease, congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies, pulmonary hypertension owing to lung diseases and/or hypoxia, , Interstitial lung disease, other pulmonary diseases with mixed restrictive and obstructive pattern, sleep-disordered breathing, alveolar hypoventilation disorders, chronic exposure to high altitude, developmental abnormalities, pulmonary hypertension defined as chronic thromboembolic pulmonary hypertension [CTEPH]), pulmonary hypertension with unclear multifactorial mechanisms, hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy, systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis, lymphangioleiomyomatosis, neurofibromatosis, vasculitis, metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders, others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental pulmonary hypertension
  • Has a history of endocrine (not including stable diabetes mellitus), gastrointestinal, cardiovascular, hematological, hepatic (not including chronic stable and ), immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Is mentally or legally incapacitated, has significant emotional problems
  • History of cancer () except nonmelanomatous skin carcinoma or carcinoma in situ of the cervix or other malignancies which have been successfully treated 10 years prior to screening
  • History of significant multiple and/or severe allergies
  • Known to iodine or iodine containing products
  • Positive for HIV
  • Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks of screening
  • Has persistent or permanent atrial fibrillation with an uncontrolled ventricular rate
  • Has significantly impaired gas exchange
  • Has an active respiratory infection (e.g. common cold, bronchitis, influenza, pneumonia) with lung function outside of the normal range
  • Is currently on monotherapy calcium channel blockers as a specific treatment for pulmonary hypertension
  • Has taken nitrates within 24 hours of anticipated dosing
  • Has taken inhaled prostacyclin within 24 hours of anticipated dosing (iloprost or treprostinil)
  • Has taken diltiazem immediate release taken within 24 hours or extended release taken within 48 hours of anticipated dosing
  • Has taken sildenafil or vardenafil within 24 hours or tadalafil within 7 days of anticipated dosing
  • Has taken soluble guanylate cyclase (sGC) activator for PAH within 24 hours of anticipated dosing
  • Is unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study drug, throughout the study (including washout intervals between treatment periods), until the poststudy visit
  • Has participated in another study within 4 weeks
  • Does not agree to follow the smoking restrictions
  • Part 2 only: Suffers from claustrophobia and would be unable to undergo computerized tomography (CT) scan
  • Part 2 only: Has participated in a positron-emission tomography (PET) research study or other study involving administration of a radioactive substance or ionizing radiation within 12 months prior to the screening visit, or has undergone or plans to have extensive radiological examination within this period
  • Consumes greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or distilled spirits [29.5 mL/1 ounce]) per day
  • Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day
  • Is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately 12 months. Participants must have a negative urine drug screen (UDS) prior to randomization
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Panel A: Frespaciguat 120 ug/165 ug/240 ug/240 ug/240 ug (Parts 1 and 2)

    Participants in Panel A will receive a single inhaled dose of frespaciguat 120 ug in Period 1 of Part 1, followed by frespaciguat 165 ug in Period 2, followed by frespaciguat 240 ug in Period 3. Each dose will be separated by at least a 7-day washout. In Part 2 Period 2, participants will receive a single inhaled dose of frespaciguat 240 ug and undergo a right heart catheterization (RHC). In Part 2 Period 3, participants will receive a single inhaled dose of frespaciguat 240 ug and undergo a functional respiratory imaging (FRI).

    Drug: Frespaciguat

  • Experimental
    Panel B: 300 ug/360 ug/360 ug (Part 2)

    Participants in Panel B will receive a single inhaled dose of frespaciguat 300 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of frespaciguat 360 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of frespaciguat 360 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.

    Drug: Frespaciguat

  • Experimental
    Panel C: 300 ug/360 ug/360 ug (Part 2, Expansion)

    Participants in Panel C will receive a single inhaled dose of frespaciguat 300 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of frespaciguat 360 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of frespaciguat 360 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.

    Drug: Frespaciguat

  • Experimental
    Panel D: 480 ug/120 ug/120 ug (Part 2)

    Participants in Panel D will receive a single inhaled dose of frespaciguat 480 ug in Period 1 of Part 2. In Period 2 of Part 2, participants will receive a single inhaled dose of frespaciguat 120 ug and undergo FRI. In Period 3 of Part 2, participants receive a single inhaled dose of frespaciguat 120 ug and undergo RHC. Each dose will be separated by at least a 7-day washout.

    Drug: Frespaciguat

  • Placebo comparator
    Placebo (Part 1)

    Participants will receive a single inhaled dose of matching placebo in Part 1.

    Drug: Placebo

Interventions

  • Single inhaled dose of frespaciguat 120, 165, 240, 300, 360, or 480 ug depending upon randomization

    Also known as: MK-5475

  • DrugPlacebo

    Single inhaled dose of placebo to match frespaciguat

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced at Least 1 Adverse Event (AE): All Parts

    An AE was defined as any untoward medical occurrence in a participant which may not necessarily have a causal relationship with the treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease that was temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The number of participants who experienced at least 1 AE was reported by dose separately for Part 1 plus Part 2 Period 1, for the RHC Period, and for the FRI Period.

    Time frame: Up to ~14 days after last dose of treatment period (Up to ~32 weeks total)

  2. Number of Participants Who Discontinued From the Study Due to an AE: All Parts

    An AE was defined as any untoward medical occurrence in a participant which may not necessarily have a causal relationship with the treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease that was temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The number of participants who discontinued from the study due to an AE was reported by dose separately for Part 1 plus Part 2 Period 1, for the RHC Period, and for the FRI Period.

    Time frame: Up to ~14 days after last dose of treatment period (Up to ~32 weeks total)

  3. Percentage Change From Baseline in Minimum Pulmonary Vascular Resistance (PVR): Part 2 Right Heart Catheterization (RHC) Period

    For each participant in the RHC Period, the percentage change from baseline for the minimum post-dose PVR value over the duration of the RHC procedure was calculated. The average of pre-dose measurements was set as the baseline. Mean (SD) percent change from baseline in PVR minimum were calculated and reported for each dose group that underwent RHC in Part 2. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

    Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and up to 4.5 hours post-dose

Secondary outcomes

  1. Change From Baseline in Heart Rate (HR) at 0.5 Hours Post-dose: Part 2 RHC Period

    HR was assessed at pre-dose in the RHC Period (baseline) and at 0.5 hours post-dose. Baseline HR and change from baseline in HR was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in HR. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

    Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 0.5 hours post-dose

  2. Change From Baseline in Heart Rate (HR) at 4.5 Hours Post-dose: Part 2 RHC Period

    HR was assessed at pre-dose in the RHC Period (baseline) and at 4.5 hours post-dose. Baseline HR and change from baseline in HR was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in HR. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

    Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 4.5 hours post-dose

  3. Change From Baseline in Heart Rate (HR) at 24 Hours Post-dose: Part 2 RHC Period

    HR was assessed at pre-dose in the RHC Period (baseline) and at 24 hours post-dose. Baseline HR and change from baseline in HR was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in HR. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

    Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 24 hours post-dose

  4. Change From Baseline in Systolic Blood Pressure (SBP) at 0.5 Hours Post-dose: Part 2 RHC Period

    SBP was assessed at pre-dose in the RHC Period (baseline) and at 0.5 hours post-dose. Baseline SBP and change from baseline in SBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in SBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

    Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 0.5 hours post-dose

  5. Change From Baseline in Systolic Blood Pressure (SBP) at 4.5 Hours Post-dose: Part 2 RHC Period

    SBP was assessed at pre-dose in the RHC Period (baseline) and at 4.5 hours post-dose. Baseline SBP and change from baseline in SBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in SBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

    Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 4.5 hours post-dose

  6. Change From Baseline in Systolic Blood Pressure (SBP) at 24 Hours Post-dose: Part 2 RHC Period

    SBP was assessed at pre-dose in the RHC Period (baseline) and at 24 hours post-dose. Baseline SBP and change from baseline in SBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in SBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

    Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 24 hours post-dose

  7. Change From Baseline in Diastolic Blood Pressure (DBP) at 0.5 Hours Post-dose: Part 2 RHC Period

    DBP was assessed at pre-dose in the RHC Period (baseline) and at 0.5 hours post-dose. Baseline DBP and change from baseline in DBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in DBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

    Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 0.5 hours post-dose

  8. Change From Baseline in Diastolic Blood Pressure (DBP) at 4.5 Hours Post-dose: Part 2 RHC Period

    DBP was assessed at pre-dose in the RHC Period (baseline) and at 4.5 hours post-dose. Baseline DBP and change from baseline in DBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in DBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

    Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 4.5 hours post-dose

  9. Change From Baseline in Diastolic Blood Pressure (DBP) at 24 Hours Post-dose: Part 2 RHC Period

    DBP was assessed at pre-dose in the RHC Period (baseline) and at 24 hours post-dose. Baseline DBP and change from baseline in DBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in DBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

    Time frame: Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 24 hours post-dose

  10. Area Under the Concentration-Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-5475: All Parts

    Blood samples were taken at predose and at specified time points postdose to determine the AUC0-inf of MK-5475. AUC0-inf was defined as the area under the concentration-time curve of MK-5475 from time zero to infinity. MK-5475 AUC0-inf was reported by panel/dose group. Per protocol, percent geometric coefficient of variation (%GCV) values were not reported for groups with n\<2 participants.

    Time frame: Part 1 and Part 2 Period 1: Predose and 0.1, 0.25, 0.5, 1, 2, 3, 4, 8, and 24 hours post-dose; RHC Period: predose and 0.25, 0.5, 1, 2, 3, 4, and 4.5 hours; FRI Period: predose and 1, 3, 8, and 24 hours postdose (Panel D also 0.25, 0.5, 2, 4 hours)

  11. Area Under the Concentration-Time Curve From Hour 0 to 24 Hours (AUC0-24hr) of MK-5475: All Parts

    Blood samples were taken at predose and at specified time points postdose to determine the AUC0-24hr of MK-5475. AUC0-24hr was defined as the area under the concentration-time curve of MK-5475 from time zero to 24 hours. MK-5475 AUC0-24hr was reported by panel/dose group. For RHC panel/dose groups where sampling was only done up to 4.5 hours, the AUC0-24hr geometric mean represents an extrapolated AUC0-24hr value. Per protocol, %GCV values were not reported for groups with n\<2 participants.

    Time frame: Part 1 and Part 2 Period 1: Predose and 0.1, 0.25, 0.5, 1, 2, 3, 4, 8, and 24 hours post-dose; RHC Period: predose and 0.25, 0.5, 1, 2, 3, 4, and 4.5 hours; FRI Period: predose and 1, 3, 8, and 24 hours postdose (Panel D also 0.25, 0.5, 2, 4 hours)

  12. Maximum Concentration (Cmax) of MK-5475: All Parts

    Blood samples were taken at predose and at specified time points postdose to determine the Cmax of MK-5475. Cmax was defined as the maximum concentration of MK-5475 reached. MK-5475 Cmax was reported by panel/dose group. Per protocol, %GCV values were not reported for groups with n\<2 participants.

    Time frame: Part 1 and Part 2 Period 1: Predose and 0.1, 0.25, 0.5, 1, 2, 3, 4, 8, and 24 hours post-dose; RHC Period: predose and 0.25, 0.5, 1, 2, 3, 4, and 4.5 hours; FRI Period: predose and 1, 3, 8, and 24 hours postdose (Panel D also 0.25, 0.5, 2, 4 hours)

  13. Concentration of MK-5475 at 24 Hours Postdose (C24): All Parts

    Blood samples were taken at predose and at specified time points postdose to determine the C24 of MK-5475. C24 was defined as the concentration of MK-5475 reached at 24 hours. MK-5475 Cmax was reported by panel/dose group. Per protocol, %GCV values were not reported for groups with n\<2 participants.

    Time frame: 24 hours postdose

  14. Time to Maximum Concentration (Tmax) of MK-5475: All Parts

    Blood samples were taken at predose and at specified time points postdose to determine the Tmax of MK-5475. Tmax was defined as the time to maximum concentration of MK-5475. MK-5475 Tmax was reported by panel/dose group.

    Time frame: Part 1 and Part 2 Period 1: Predose and 0.1, 0.25, 0.5, 1, 2, 3, 4, 8, and 24 hours post-dose; RHC Period: predose and 0.25, 0.5, 1, 2, 3, 4, and 4.5 hours; FRI Period: predose and 1, 3, 8, and 24 hours postdose (Panel D also 0.25, 0.5, 2, 4 hours)

  15. Apparent Terminal Half-life (t1/2) of MK-5475: All Parts

    Blood samples were taken at predose and at specified time points postdose to determine the t½ of MK-5475. t½ was defined as the time required to divide the MK-5475 plasma concentration by two after reaching pseudo-equilibrium, following a single dose of MK-5475. MK-5475 t½ was reported by panel/dose group.

    Time frame: Part 1 and Part 2 Period 1: Predose and 0.1, 0.25, 0.5, 1, 2, 3, 4, 8, and 24 hours post-dose; RHC Period: predose and 0.25, 0.5, 1, 2, 3, 4, and 4.5 hours; FRI Period: predose and 1, 3, 8, and 24 hours postdose (Panel D also 0.25, 0.5, 2, 4 hours)

  16. Percentage Change From Baseline in Pulmonary Blood Volume (PBV) Over Time: Part 2 Functional Respiratory Imaging (FRI) Period

    Participants underwent a series of computed tomography (CT) scans with an intravenous (IV) iodinated contrast agent to facilitate assessment of PBV at baseline and at several times points after MK-5475 dosing. Percentage change from baseline (CFB) in PBV was calculated and reported for each dose group that underwent FRI in Part 2. As pre-specified, central tendency for PBV percentage CFB was provided as numerical values rounded to whole numbers. Per protocol, this outcome measure was only assessed during the Part 2 FRI Period for each panel and was not assessed during Part 1.

    Time frame: Baseline: Pre-dose on Day 1 of FRI Period (up to 227 days) and 1, 3, 8, and 24 hours post-dose

07

Results

Posted Feb 23, 2022

Participant flow

Adult participants with Group 1 Pulmonary Arterial Hypertension (PAH) were recruited to evaluate safety, pharmacokinetics (PK), Functional Respiratory Imaging (FRI), and Right Heart Catheterization (RHC) of single-dose MK-5475.

Participant flow — Overall Study
MilestoneMK-5475 120 ug/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A)MK-5475 120 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A)MK-5475 120 ug/MK-5475 165 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug (Panel A)Placebo/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A)Placebo/MK-5475 165 ug/MK-5475 240 ug (Panel A)MK-5475 300 ug/ MK-5475 165 ug/ MK-5475 165 ug (Panel B)MK-5475 300 ug/ MK-5475 360 ug/ MK-5475 360 ug (Panels B+C)MK-5475 300 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel C)MK-5475 480 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel D)MK-5475 480 ug/ MK-5475 120 ug (Panel D)
Started2221118431
Completed2221118431
Not completed0000000000

Outcome measures

PrimaryNumber of Participants Who Experienced at Least 1 Adverse Event (AE): All Parts

An AE was defined as any untoward medical occurrence in a participant which may not necessarily have a causal relationship with the treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease that was temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The number of participants who experienced at least 1 AE was reported by dose separately for Part 1 plus Part 2 Period 1, for the RHC Period, and for the FRI Period.

Time frame:
Up to ~14 days after last dose of treatment period (Up to ~32 weeks total)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced at Least 1 Adverse Event (AE): All Parts
ParticipantsMK-5475 120 ug: Part 1 (Panel A)MK-5475 165 ug: Part 1 (Panel A)MK-5475 240 ug: Part 1 (Panel A)MK-5475 300 ug: Part 2 Period 1 (Panels B+C)MK-5475 480 ug: Part 2 Period 1 (Panel D)Placebo: Part 1MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panels B+C)MK-5475 120 ug: FRI (Panels C+D)MK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRI (Panel A)MK-5475 360 ug: FRI (Panels B+C)
Number of Participants Who Experienced at Least 1 Adverse Event (AE): All Parts21352451641004
PrimaryNumber of Participants Who Discontinued From the Study Due to an AE: All Parts

An AE was defined as any untoward medical occurrence in a participant which may not necessarily have a causal relationship with the treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease that was temporally associated with use of a medicinal product, regardless of whether or not it was considered related to the medicinal product. The number of participants who discontinued from the study due to an AE was reported by dose separately for Part 1 plus Part 2 Period 1, for the RHC Period, and for the FRI Period.

Time frame:
Up to ~14 days after last dose of treatment period (Up to ~32 weeks total)
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued From the Study Due to an AE: All Parts
ParticipantsMK-5475 120 ug: Part 1 (Panel A)MK-5475 165 ug: Part 1 (Panel A)MK-5475 240 ug: Part 1 (Panel A)MK-5475 300 ug: Part 2 Period 1 (Panels B+C)MK-5475 480 ug: Part 2 Period 1 (Panel D)Placebo: Part 1MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panels B+C)MK-5475 120 ug: FRI (Panels C+D)MK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRI (Panel A)MK-5475 360 ug: FRI (Panels B+C)
Number of Participants Who Discontinued From the Study Due to an AE: All Parts00000000000000
PrimaryPercentage Change From Baseline in Minimum Pulmonary Vascular Resistance (PVR): Part 2 Right Heart Catheterization (RHC) Period

For each participant in the RHC Period, the percentage change from baseline for the minimum post-dose PVR value over the duration of the RHC procedure was calculated. The average of pre-dose measurements was set as the baseline. Mean (SD) percent change from baseline in PVR minimum were calculated and reported for each dose group that underwent RHC in Part 2. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

Time frame:
Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and up to 4.5 hours post-dose
Reported as:
Mean · Percentage change
Percentage Change From Baseline in Minimum Pulmonary Vascular Resistance (PVR): Part 2 Right Heart Catheterization (RHC) Period
Percentage changeMK-5475 120 ug: Part 1 (Panel A)MK-5475 165 ug: Part 1 (Panel A)MK-5475 240 ug: Part 1 (Panel A)MK-5475 300 ug: Part 2 Period 1 (Panels B+C)MK-5475 480 ug: Part 2 Period 1 (Panel D)Placebo: Part 1MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panels B+C)MK-5475 120 ug: FRI (Panels C+D)MK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRI (Panel A)MK-5475 360 ug: FRI (Panels B+C)
Percentage Change From Baseline in Minimum Pulmonary Vascular Resistance (PVR): Part 2 Right Heart Catheterization (RHC) Period——————-20.77 ± 13.8813.01 ± NA-29.46 ± 13.72-29.25 ± 17.58————
SecondaryChange From Baseline in Heart Rate (HR) at 0.5 Hours Post-dose: Part 2 RHC Period

HR was assessed at pre-dose in the RHC Period (baseline) and at 0.5 hours post-dose. Baseline HR and change from baseline in HR was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in HR. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

Time frame:
Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 0.5 hours post-dose
Reported as:
Mean · beats/minute
Change From Baseline in Heart Rate (HR) at 0.5 Hours Post-dose: Part 2 RHC Period
beats/minuteMK-5475 120 ug: Part 1MK-5475 165 ug: Part 1MK-5475 240 ug: Part 1MK-5475 300 ug: Part 2 Period 1MK-5475 480 ug: Part 2 Period 1Placebo: Part 1MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panel B)MK-5475 360 ug: RHC (Panel C)MK-5475 120 ug: FRIMK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRIMK-5475 360 ug: FRI
Baseline HR——————74.75 ± 9.78—62.57 ± 6.2368.75 ± 2.3669.06 ± 4.29————
Change from Baseline in HR——————3.56 ± 7.60—1.83 ± 1.564.92 ± 3.03-2.76 ± 1.60————
SecondaryChange From Baseline in Heart Rate (HR) at 4.5 Hours Post-dose: Part 2 RHC Period

HR was assessed at pre-dose in the RHC Period (baseline) and at 4.5 hours post-dose. Baseline HR and change from baseline in HR was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in HR. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

Time frame:
Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 4.5 hours post-dose
Reported as:
Mean · beats/minute
Change From Baseline in Heart Rate (HR) at 4.5 Hours Post-dose: Part 2 RHC Period
beats/minuteMK-5475 120 ug: Part 1MK-5475 165 ug: Part 1MK-5475 240 ug: Part 1MK-5475 300 ug: Part 2 Period 1MK-5475 480 ug: Part 2 Period 1Placebo: Part 1MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panel B)MK-5475 360 ug: RHC (Panel C)MK-5475 120 ug: FRIMK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRIMK-5475 360 ug: FRI
Baseline HR——————74.75 ± 9.78—62.57 ± 6.2368.75 ± 2.3669.06 ± 4.29————
Change from Baseline in HR——————-0.56 ± 4.55—3.20 ± 3.517.17 ± 1.55-0.98 ± 2.01————
SecondaryChange From Baseline in Heart Rate (HR) at 24 Hours Post-dose: Part 2 RHC Period

HR was assessed at pre-dose in the RHC Period (baseline) and at 24 hours post-dose. Baseline HR and change from baseline in HR was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in HR. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

Time frame:
Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 24 hours post-dose
Reported as:
Mean · beats/minute
Change From Baseline in Heart Rate (HR) at 24 Hours Post-dose: Part 2 RHC Period
beats/minuteMK-5475 120 ug: Part 1MK-5475 165 ug: Part 1MK-5475 240 ug: Part 1MK-5475 300 ug: Part 2 Period 1MK-5475 480 ug: Part 2 Period 1Placebo: Part 1MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panel B)MK-5475 360 ug: RHC (Panel C)MK-5475 120 ug: FRIMK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRIMK-5475 360 ug: FRI
Baseline HR——————74.75 ± 9.78—62.57 ± 6.2368.75 ± 2.3669.06 ± 4.29————
Change from Baseline in HR——————1.78 ± 7.35—7.43 ± 3.322.42 ± 3.10-0.72 ± 2.53————
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) at 0.5 Hours Post-dose: Part 2 RHC Period

SBP was assessed at pre-dose in the RHC Period (baseline) and at 0.5 hours post-dose. Baseline SBP and change from baseline in SBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in SBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

Time frame:
Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 0.5 hours post-dose
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) at 0.5 Hours Post-dose: Part 2 RHC Period
Millimeters of mercury (mmHg)MK-5475 120 ug: Part 1MK-5475 165 ug: Part 1MK-5475 240 ug: Part 1MK-5475 300 ug: Part 2 Period 1MK-5475 480 ug: Part 2 Period 1Placebo: Part 1MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panel B)MK-5475 360 ug: RHC (Panel C)MK-5475 120 ug: FRIMK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRIMK-5475 360 ug: FRI
Baseline SBP——————123.25 ± 9.80—132.86 ± 3.79128.50 ± 9.65119.11 ± 4.72————
Change from Baseline in SBP——————25.33 ± 2.52—2.67 ± 3.70-1.17 ± 3.465.30 ± 2.36————
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) at 4.5 Hours Post-dose: Part 2 RHC Period

SBP was assessed at pre-dose in the RHC Period (baseline) and at 4.5 hours post-dose. Baseline SBP and change from baseline in SBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in SBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

Time frame:
Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 4.5 hours post-dose
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) at 4.5 Hours Post-dose: Part 2 RHC Period
Millimeters of mercury (mmHg)MK-5475 120 ug: Part 1MK-5475 165 ug: Part 1MK-5475 240 ug: Part 1MK-5475 300 ug: Part 2 Period 1MK-5475 480 ug: Part 2 Period 1Placebo: Part 1MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panel B)MK-5475 360 ug: RHC (Panel C)MK-5475 120 ug: FRIMK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRIMK-5475 360 ug: FRI
Baseline SBP——————123.25 ± 9.80—132.86 ± 3.79128.50 ± 9.65119.11 ± 4.72————
Change from Baseline in SBP——————10.67 ± 0.38—4.93 ± 5.657.50 ± 1.5511.96 ± 6.31————
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) at 24 Hours Post-dose: Part 2 RHC Period

SBP was assessed at pre-dose in the RHC Period (baseline) and at 24 hours post-dose. Baseline SBP and change from baseline in SBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in SBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

Time frame:
Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 24 hours post-dose
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) at 24 Hours Post-dose: Part 2 RHC Period
Millimeters of mercury (mmHg)MK-5475 120 ug: Part 1MK-5475 165 ug: Part 1MK-5475 240 ug: Part 1MK-5475 300 ug: Part 2 Period 1MK-5475 480 ug: Part 2 Period 1Placebo: Part 1MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panel B)MK-5475 360 ug: RHC (Panel C)MK-5475 120 ug: FRIMK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRIMK-5475 360 ug: FRI
Baseline SBP——————123.25 ± 9.80—132.86 ± 3.79128.50 ± 9.65119.11 ± 4.72————
Change from Baseline in SBP——————6.22 ± 5.28—-5.95 ± 5.782.25 ± 7.620.74 ± 3.44————
SecondaryChange From Baseline in Diastolic Blood Pressure (DBP) at 0.5 Hours Post-dose: Part 2 RHC Period

DBP was assessed at pre-dose in the RHC Period (baseline) and at 0.5 hours post-dose. Baseline DBP and change from baseline in DBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in DBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

Time frame:
Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 0.5 hours post-dose
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Diastolic Blood Pressure (DBP) at 0.5 Hours Post-dose: Part 2 RHC Period
Millimeters of mercury (mmHg)MK-5475 120 ug: Part 1MK-5475 165 ug: Part 1MK-5475 240 ug: Part 1MK-5475 300 ug: Part 2 Period 1MK-5475 480 ug: Part 2 Period 1Placebo: Part 1MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panel B)MK-5475 360 ug: RHC (Panel C)MK-5475 120 ug: FRIMK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRIMK-5475 360 ug: FRI
Baseline DBP——————69.75 ± 4.03—72.43 ± 2.2577.00 ± 4.9570.78 ± 3.52————
Change from Baseline in DBP——————4.00 ± 4.60—0.94 ± 1.680.75 ± 3.481.30 ± 1.75————
SecondaryChange From Baseline in Diastolic Blood Pressure (DBP) at 4.5 Hours Post-dose: Part 2 RHC Period

DBP was assessed at pre-dose in the RHC Period (baseline) and at 4.5 hours post-dose. Baseline DBP and change from baseline in DBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in DBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

Time frame:
Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 4.5 hours post-dose
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Diastolic Blood Pressure (DBP) at 4.5 Hours Post-dose: Part 2 RHC Period
Millimeters of mercury (mmHg)MK-5475 120 ug: Part 1MK-5475 165 ug: Part 1MK-5475 240 ug: Part 1MK-5475 300 ug: Part 2 Period 1MK-5475 480 ug: Part 2 Period 1Placebo: Part 1MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panel B)MK-5475 360 ug: RHC (Panel C)MK-5475 120 ug: FRIMK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRIMK-5475 360 ug: FRI
Baseline DBP——————69.75 ± 4.03—72.43 ± 2.2577.00 ± 4.9570.78 ± 3.52————
Change from Baseline in DBP——————-0.22 ± 4.87—1.07 ± 2.343.58 ± 2.734.00 ± 4.28————
SecondaryChange From Baseline in Diastolic Blood Pressure (DBP) at 24 Hours Post-dose: Part 2 RHC Period

DBP was assessed at pre-dose in the RHC Period (baseline) and at 24 hours post-dose. Baseline DBP and change from baseline in DBP was reported for each panel/dose group that underwent RHC in Part 2, according to treatment planned. Negative values indicate decreases from baseline in DBP. Per protocol, this outcome measure was only assessed during the Part 2 RHC Period for each panel and was not assessed during Part 1.

Time frame:
Baseline: Pre-dose on Day 1 of RHC Period (up to 185 days) and 24 hours post-dose
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Diastolic Blood Pressure (DBP) at 24 Hours Post-dose: Part 2 RHC Period
Millimeters of mercury (mmHg)MK-5475 120 ug: Part 1MK-5475 165 ug: Part 1MK-5475 240 ug: Part 1MK-5475 300 ug: Part 2 Period 1MK-5475 480 ug: Part 2 Period 1Placebo: Part 1MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panel B)MK-5475 360 ug: RHC (Panel C)MK-5475 120 ug: FRIMK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRIMK-5475 360 ug: FRI
Baseline SBP——————69.75 ± 4.03—72.43 ± 2.2577.00 ± 4.9570.78 ± 3.52————
Change from Baseline in SBP——————-1.44 ± 0.89—-2.76 ± 3.222.42 ± 3.15-1.74 ± 2.89————
SecondaryArea Under the Concentration-Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-5475: All Parts

Blood samples were taken at predose and at specified time points postdose to determine the AUC0-inf of MK-5475. AUC0-inf was defined as the area under the concentration-time curve of MK-5475 from time zero to infinity. MK-5475 AUC0-inf was reported by panel/dose group. Per protocol, percent geometric coefficient of variation (%GCV) values were not reported for groups with n\<2 participants.

Time frame:
Part 1 and Part 2 Period 1: Predose and 0.1, 0.25, 0.5, 1, 2, 3, 4, 8, and 24 hours post-dose; RHC Period: predose and 0.25, 0.5, 1, 2, 3, 4, and 4.5 hours; FRI Period: predose and 1, 3, 8, and 24 hours postdose (Panel D also 0.25, 0.5, 2, 4 hours)
Reported as:
Geometric mean · nM*hr
Area Under the Concentration-Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-5475: All Parts
nM*hrMK-5475 120 ug: Part 1 (Panel A)MK-5475 165 ug: Part 1 (Panel A)MK-5475 240 ug: Part 1 (Panel A)MK-5475 300 ug: Part 2 Period 1 (Panel B)MK-5475 300 ug: Part 2 Period 1 (Panel C)MK-5475 480 ug: Part 2 Period 1 (Panel D)Placebo: Part 1MK-5475 120 ug: RHC (Panel C)MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panel B)MK-5475 360 ug: RHC (Panel C)MK-5475 120 ug: FRI (Panel C)MK-5475 120 ug: FRI (Panel D)MK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRI (Panel A)MK-5475 360 ug: FRI (Panel B)MK-5475 360 ug: FRI (Panel C)
Area Under the Concentration-Time Curve From Hour 0 to Infinity (AUC0-inf) of MK-5475: All Parts1.00 ± 45.50.721 ± 103.61.25 ± 59.72.15 ± 106.31.66 ± 66.84.59 ± 20.9—1.03 ± 20.01.05 ± 28.9—1.03 ± 59.71.46 ± 63.23.46 ± 67.30.748 ± 43.90.978 ± 18.34.26 ± NA——4.10 ± 37.6
SecondaryArea Under the Concentration-Time Curve From Hour 0 to 24 Hours (AUC0-24hr) of MK-5475: All Parts

Blood samples were taken at predose and at specified time points postdose to determine the AUC0-24hr of MK-5475. AUC0-24hr was defined as the area under the concentration-time curve of MK-5475 from time zero to 24 hours. MK-5475 AUC0-24hr was reported by panel/dose group. For RHC panel/dose groups where sampling was only done up to 4.5 hours, the AUC0-24hr geometric mean represents an extrapolated AUC0-24hr value. Per protocol, %GCV values were not reported for groups with n\<2 participants.

Time frame:
Part 1 and Part 2 Period 1: Predose and 0.1, 0.25, 0.5, 1, 2, 3, 4, 8, and 24 hours post-dose; RHC Period: predose and 0.25, 0.5, 1, 2, 3, 4, and 4.5 hours; FRI Period: predose and 1, 3, 8, and 24 hours postdose (Panel D also 0.25, 0.5, 2, 4 hours)
Reported as:
Geometric mean · nM*hr
Area Under the Concentration-Time Curve From Hour 0 to 24 Hours (AUC0-24hr) of MK-5475: All Parts
nM*hrMK-5475 120 ug: Part 1 (Panel A)MK-5475 165 ug: Part 1 (Panel A)MK-5475 240 ug: Part 1 (Panel A)MK-5475 300 ug: Part 2 Period 1 (Panel B)MK-5475 300 ug: Part 2 Period 1 (Panel C)MK-5475 480 ug: Part 2 Period 1 (Panel D)Placebo: Part 1MK-5475 120 ug: RHC (Panel C)MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panel B)MK-5475 360 ug: RHC (Panel C)MK-5475 120 ug: FRI (Panel C)MK-5475 120 ug: FRI (Panel D)MK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRI (Panel A)MK-5475 360 ug: FRI (Panel B)MK-5475 360 ug: FRI (Panel C)
Area Under the Concentration-Time Curve From Hour 0 to 24 Hours (AUC0-24hr) of MK-5475: All Parts0.259 ± 288.20.613 ± 136.01.42 ± 59.92.35 ± 96.21.82 ± 63.24.53 ± 21.0—1.02 ± 18.51.05 ± 28.9NA ± NA1.04 ± 59.01.45 ± 61.73.48 ± 68.30.747 ± 43.51.13 ± 18.44.19 ± NA1.71 ± 43.31.21 ± 80.13.82 ± 35.3
SecondaryMaximum Concentration (Cmax) of MK-5475: All Parts

Blood samples were taken at predose and at specified time points postdose to determine the Cmax of MK-5475. Cmax was defined as the maximum concentration of MK-5475 reached. MK-5475 Cmax was reported by panel/dose group. Per protocol, %GCV values were not reported for groups with n\<2 participants.

Time frame:
Part 1 and Part 2 Period 1: Predose and 0.1, 0.25, 0.5, 1, 2, 3, 4, 8, and 24 hours post-dose; RHC Period: predose and 0.25, 0.5, 1, 2, 3, 4, and 4.5 hours; FRI Period: predose and 1, 3, 8, and 24 hours postdose (Panel D also 0.25, 0.5, 2, 4 hours)
Reported as:
Geometric mean · nM
Maximum Concentration (Cmax) of MK-5475: All Parts
nMMK-5475 120 ug: Part 1 (Panel A)MK-5475 165 ug: Part 1 (Panel A)MK-5475 240 ug: Part 1 (Panel A)MK-5475 300 ug: Part 2 Period 1 (Panel B)MK-5475 300 ug: Part 2 Period 1 (Panel C)MK-5475 480 ug: Part 2 Period 1 (Panel D)Placebo: Part 1MK-5475 120 ug: RHC (Panel C)MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panel B)MK-5475 360 ug: RHC (Panel C)MK-5475 120 ug: FRI (Panel C)MK-5475 120 ug: FRI (Panel D)MK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRI (Panel A)MK-5475 360 ug: FRI (Panel B)MK-5475 360 ug: FRI (Panel C)
Maximum Concentration (Cmax) of MK-5475: All Parts0.0722 ± 153.30.139 ± 117.90.297 ± 60.80.543 ± 73.90.409 ± 66.00.981 ± 22.9—0.218 ± 4.70.161 ± 76.50.312 ± NA0.202 ± 59.70.307 ± 21.70.960 ± 67.90.228 ± 36.80.245 ± 21.70.601 ± NA0.341 ± 40.10.301 ± 69.80.915 ± 56.5
SecondaryConcentration of MK-5475 at 24 Hours Postdose (C24): All Parts

Blood samples were taken at predose and at specified time points postdose to determine the C24 of MK-5475. C24 was defined as the concentration of MK-5475 reached at 24 hours. MK-5475 Cmax was reported by panel/dose group. Per protocol, %GCV values were not reported for groups with n\<2 participants.

Time frame:
24 hours postdose
Reported as:
Geometric mean · nM
Concentration of MK-5475 at 24 Hours Postdose (C24): All Parts
nMMK-5475 120 ug: Part 1 (Panel A)MK-5475 165 ug: Part 1 (Panel A)MK-5475 240 ug: Part 1 (Panel A)MK-5475 300 ug: Part 2 Period 1 (Panel B)MK-5475 300 ug: Part 2 Period 1 (Panel C)MK-5475 480 ug: Part 2 Period 1 (Panel D)Placebo: Part 1MK-5475 120 ug: RHC (Panel C)MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panel B)MK-5475 360 ug: RHC (Panel C)MK-5475 120 ug: FRI (Panel C)MK-5475 120 ug: FRI (Panel D)MK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRI (Panel A)MK-5475 360 ug: FRI (Panel B)MK-5475 360 ug: FRI (Panel C)
Concentration of MK-5475 at 24 Hours Postdose (C24): All PartsNA ± NANA ± NANA ± NANA ± NANA ± NA0.0113 ± 25.0—NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA0.0128 ± NANA ± NANA ± NANA ± NA
SecondaryTime to Maximum Concentration (Tmax) of MK-5475: All Parts

Blood samples were taken at predose and at specified time points postdose to determine the Tmax of MK-5475. Tmax was defined as the time to maximum concentration of MK-5475. MK-5475 Tmax was reported by panel/dose group.

Time frame:
Part 1 and Part 2 Period 1: Predose and 0.1, 0.25, 0.5, 1, 2, 3, 4, 8, and 24 hours post-dose; RHC Period: predose and 0.25, 0.5, 1, 2, 3, 4, and 4.5 hours; FRI Period: predose and 1, 3, 8, and 24 hours postdose (Panel D also 0.25, 0.5, 2, 4 hours)
Reported as:
Median · Hour
Time to Maximum Concentration (Tmax) of MK-5475: All Parts
HourMK-5475 120 ug: Part 1 (Panel A)MK-5475 165 ug: Part 1 (Panel A)MK-5475 240 ug: Part 1 (Panel A)MK-5475 300 ug: Part 2 Period 1 (Panel B)MK-5475 300 ug: Part 2 Period 1 (Panel C)MK-5475 480 ug: Part 2 Period 1 (Panel D)Placebo: Part 1MK-5475 120 ug: RHC (Panel C)MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panel B)MK-5475 360 ug: RHC (Panel C)MK-5475 120 ug: FRI (Panel C)MK-5475 120 ug: FRI (Panel D)MK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRI (Panel A)MK-5475 360 ug: FRI (Panel B)MK-5475 360 ug: FRI (Panel C)
Time to Maximum Concentration (Tmax) of MK-5475: All Parts2.00 (2.00 to 2.00)1.00 (1.00 to 2.00)2.00 (1.00 to 2.00)1.50 (1.00 to 2.00)1.00 (1.00 to 2.00)1.00 (1.00 to 2.00)—1.00 (0.50 to 1.00)1.00 (0.00 to 1.00)3.00 (3.00 to 3.00)2.00 (1.00 to 3.00)1.00 (1.00 to 1.00)1.00 (0.50 to 1.00)1.00 (1.00 to 3.00)1.50 (1.00 to 2.00)1.00 (1.00 to 1.00)1.00 (1.00 to 3.00)1.00 (1.00 to 3.00)1.00 (1.00 to 1.00)
SecondaryApparent Terminal Half-life (t1/2) of MK-5475: All Parts

Blood samples were taken at predose and at specified time points postdose to determine the t½ of MK-5475. t½ was defined as the time required to divide the MK-5475 plasma concentration by two after reaching pseudo-equilibrium, following a single dose of MK-5475. MK-5475 t½ was reported by panel/dose group.

Time frame:
Part 1 and Part 2 Period 1: Predose and 0.1, 0.25, 0.5, 1, 2, 3, 4, 8, and 24 hours post-dose; RHC Period: predose and 0.25, 0.5, 1, 2, 3, 4, and 4.5 hours; FRI Period: predose and 1, 3, 8, and 24 hours postdose (Panel D also 0.25, 0.5, 2, 4 hours)
Reported as:
Geometric mean · Hour
Apparent Terminal Half-life (t1/2) of MK-5475: All Parts
HourMK-5475 120 ug: Part 1 (Panel A)MK-5475 165 ug: Part 1 (Panel A)MK-5475 240 ug: Part 1 (Panel A)MK-5475 300 ug: Part 2 Period 1 (Panel B)MK-5475 300 ug: Part 2 Period 1 (Panel C)MK-5475 480 ug: Part 2 Period 1 (Panel D)Placebo: Part 1MK-5475 120 ug: RHC (Panel C)MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panel B)MK-5475 360 ug: RHC (Panel C)MK-5475 120 ug: FRI (Panel C)MK-5475 120 ug: FRI (Panel D)MK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRI (Panel A)MK-5475 360 ug: FRI (Panel B)MK-5475 360 ug: FRI (Panel C)
Apparent Terminal Half-life (t1/2) of MK-5475: All Parts1.73 ± 11.41.76 ± 10.91.87 ± 13.52.12 ± 37.22.18 ± 37.93.67 ± 6.6—2.82 ± 10.52.32 ± 21.0—2.35 ± 9.23.13 ± 45.52.05 ± 11.62.45 ± 24.62.19 ± 8.13.89 ± NA——3.92 ± 7.9
SecondaryPercentage Change From Baseline in Pulmonary Blood Volume (PBV) Over Time: Part 2 Functional Respiratory Imaging (FRI) Period

Participants underwent a series of computed tomography (CT) scans with an intravenous (IV) iodinated contrast agent to facilitate assessment of PBV at baseline and at several times points after MK-5475 dosing. Percentage change from baseline (CFB) in PBV was calculated and reported for each dose group that underwent FRI in Part 2. As pre-specified, central tendency for PBV percentage CFB was provided as numerical values rounded to whole numbers. Per protocol, this outcome measure was only assessed during the Part 2 FRI Period for each panel and was not assessed during Part 1.

Time frame:
Baseline: Pre-dose on Day 1 of FRI Period (up to 227 days) and 1, 3, 8, and 24 hours post-dose
Reported as:
Number · Percentage change
Percentage Change From Baseline in Pulmonary Blood Volume (PBV) Over Time: Part 2 Functional Respiratory Imaging (FRI) Period
Percentage changeMK-5475 120 ug: Part 1 (Panel A)MK-5475 165 ug: Part 1 (Panel A)MK-5475 240 ug: Part 1 (Panel A)MK-5475 300 ug: Part 2 Period 1 (Panels B+C)MK-5475 480 ug: Part 2 Period 1 (Panel D)Placebo: Part 1MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panels B+C)MK-5475 120 ug: FRI (Panels C+D)MK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRI (Panel A)MK-5475 360 ug: FRI (Panels B+C)
CFB at 1 hour——————————-2—23
CFB at 3 hours——————————2—29
CFB at 8 hours——————————3—119
CFB at 24 hours——————————-2—36

Adverse events

Collected over Up to ~14 days after last dose of treatment period (Up to ~32 weeks total). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-5475 120 ug: Part 1 (Panel A)0/6 (0%)0/6 (0%)2/6 (33.3%)
MK-5475 165 ug: Part 1 (Panel A)0/6 (0%)0/6 (0%)1/6 (16.7%)
MK-5475 240 ug: Part 1 (Panel A)0/6 (0%)0/6 (0%)3/6 (50%)
MK-5475 300 ug: Part 2 Period 1 (Panels B+C)0/13 (0%)0/13 (0%)5/13 (38.5%)
MK-5475 480 ug: Part 2 Period 1 (Panel D)0/4 (0%)0/4 (0%)2/4 (50%)
Placebo: Part 10/6 (0%)0/6 (0%)4/6 (66.7%)
MK-5475 120 ug: RHC (Panel D)0/7 (0%)0/7 (0%)5/7 (71.4%)
MK-5475 165 ug: RHC (Panel B)0/1 (0%)0/1 (0%)1/1 (100%)
MK-5475 240 ug: RHC (Panel A)0/7 (0%)0/7 (0%)6/7 (85.7%)
MK-5475 360 ug: RHC (Panels B+C)0/8 (0%)0/8 (0%)4/8 (50%)
MK-5475 120 ug: FRI (Panels C+D)0/8 (0%)0/8 (0%)1/8 (12.5%)
MK-5475 165 ug: FRI (Panel B)0/1 (0%)0/1 (0%)0/1 (0%)
MK-5475 240 ug: FRI (Panel A)0/7 (0%)0/7 (0%)0/7 (0%)
MK-5475 360 ug: FRI (Panels B+C)0/8 (0%)0/8 (0%)4/8 (50%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventMK-5475 120 ug: Part 1 (Panel A)MK-5475 165 ug: Part 1 (Panel A)MK-5475 240 ug: Part 1 (Panel A)MK-5475 300 ug: Part 2 Period 1 (Panels B+C)MK-5475 480 ug: Part 2 Period 1 (Panel D)Placebo: Part 1MK-5475 120 ug: RHC (Panel D)MK-5475 165 ug: RHC (Panel B)MK-5475 240 ug: RHC (Panel A)MK-5475 360 ug: RHC (Panels B+C)MK-5475 120 ug: FRI (Panels C+D)MK-5475 165 ug: FRI (Panel B)MK-5475 240 ug: FRI (Panel A)MK-5475 360 ug: FRI (Panels B+C)
Back painMusculoskeletal and connective tissue disorders0/60/62/60/130/40/63/71/14/73/80/80/10/70/8
Blood bilirubin increasedInvestigations0/60/61/60/131/42/60/70/10/70/80/80/10/71/8
FatigueGeneral disorders0/60/60/60/130/40/62/70/10/70/80/80/10/70/8
Blood creatinine increasedInvestigations0/60/60/60/131/41/60/70/10/70/80/80/10/70/8
RhinitisInfections and infestations0/60/60/60/130/41/60/70/10/70/80/80/10/70/8
Urinary tract infectionInfections and infestations1/60/60/61/130/40/60/70/10/70/80/80/10/70/8
Alanine aminotransferase increasedInvestigations1/60/60/60/130/40/60/70/10/70/80/80/10/70/8
HyperkalaemiaMetabolism and nutrition disorders0/61/61/61/130/40/60/70/10/71/80/80/10/70/8
DizzinessNervous system disorders0/60/60/60/130/41/60/70/11/70/80/80/10/70/8
Bronchitis chronicRespiratory, thoracic and mediastinal disorders0/60/60/60/130/41/60/70/10/70/80/80/10/70/8

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MK-5475 120 ug/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A)MK-5475 120 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A)MK-5475 120 ug/MK-5475 165 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug (Panel A)Placebo/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A)Placebo/MK-5475 165 ug/MK-5475 240 ug (Panel A)MK-5475 300 ug/ MK-5475 165 ug/ MK-5475 165 ug (Panel B)MK-5475 300 ug/ MK-5475 360 ug/ MK-5475 360 ug (Panels B+C)MK-5475 300 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel C)MK-5475 480 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel D)MK-5475 480 ug/ MK-5475 120 ug (Panel D)Total
Mean53.0 ± 1.451.0 ± 4.261.0 ± 4.261.0 ± NA61.0 ± NA52.0 ± NA48.6 ± 14.461.3 ± 2.262.7 ± 5.969.0 ± NA55.8 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)MK-5475 120 ug/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A)MK-5475 120 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A)MK-5475 120 ug/MK-5475 165 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug (Panel A)Placebo/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A)Placebo/MK-5475 165 ug/MK-5475 240 ug (Panel A)MK-5475 300 ug/ MK-5475 165 ug/ MK-5475 165 ug (Panel B)MK-5475 300 ug/ MK-5475 360 ug/ MK-5475 360 ug (Panels B+C)MK-5475 300 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel C)MK-5475 480 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel D)MK-5475 480 ug/ MK-5475 120 ug (Panel D)Total
Female122010632118
Male10010121107
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MK-5475 120 ug/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A)MK-5475 120 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A)MK-5475 120 ug/MK-5475 165 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug (Panel A)Placebo/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A)Placebo/MK-5475 165 ug/MK-5475 240 ug (Panel A)MK-5475 300 ug/ MK-5475 165 ug/ MK-5475 165 ug (Panel B)MK-5475 300 ug/ MK-5475 360 ug/ MK-5475 360 ug (Panels B+C)MK-5475 300 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel C)MK-5475 480 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel D)MK-5475 480 ug/ MK-5475 120 ug (Panel D)Total
Hispanic or Latino00000000000
Not Hispanic or Latino222111843125
Unknown or Not Reported00000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MK-5475 120 ug/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A)MK-5475 120 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A)MK-5475 120 ug/MK-5475 165 ug/Placebo/MK-5475 240 ug/MK-5475 240 ug (Panel A)Placebo/MK-5475 165 ug/MK-5475 240 ug/MK-5475 240 ug/MK-5475 240 ug (Panel A)Placebo/MK-5475 165 ug/MK-5475 240 ug (Panel A)MK-5475 300 ug/ MK-5475 165 ug/ MK-5475 165 ug (Panel B)MK-5475 300 ug/ MK-5475 360 ug/ MK-5475 360 ug (Panels B+C)MK-5475 300 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel C)MK-5475 480 ug/ MK-5475 120 ug/ MK-5475 120 ug (Panel D)MK-5475 480 ug/ MK-5475 120 ug (Panel D)Total
American Indian or Alaska Native00000000000
Asian00000000000
Native Hawaiian or Other Pacific Islander00000000000
Black or African American00000000000
White222111843125
More than one race00000000000
Unknown or Not Reported00000000000
08

Study locations

1 site
  • Republican Clinical Hospital of Moldova ( Site 0001)
    Chisinau, 2025, Moldova, Republic of
09

References and documents

Publications

  • Bajwa EK, Cislak D, Palcza J, Feng HP, Messina EJ, Reynders T, Denef JF, Corcea V, Lai E, Stoch SA. Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH). Respir Med. 2023 Jan;206:107065. doi: 10.1016/j.rmed.2022.107065. Epub 2022 Nov 29. PubMed 36521262 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Dec 2020, 22 months.

Results were first posted in Feb 2022, 1 year 2 months after primary completion.

Of 34 industry-sponsored phase 1 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 17. This study's 22 months is above that.

Counting every sponsor, half of 45 studies reached it within 9 months; a quarter within 2 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2018
First posted
Nov 16, 2018
StartActual
Jan 18, 2019
Primary completionActual
Dec 11, 2020
CompletionActual
Dec 11, 2020
Results first posted
Feb 23, 2022
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03744637
Responsible party
Sponsor
First posted
Nov 16, 2018
Start date
Jan 18, 2019
Primary completion
Dec 11, 2020
Completion
Dec 11, 2020
Results posted
Feb 23, 2022
Last update
Jun 4, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Frespaciguat

Start the discussion